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Bromodomain-containing protein 7miR-410 acts as an oncogene or tumor suppressor gene in some malignancies. However, its role in
NSCLC is still unknown. In this study, we showed that the expression of miR-410 was up-regulated in
both human NSCLC tissues and cells. Overexpression of miR-410 promoted cell proliferation, migra-
tion, and invasion of NSCLC. In addition, bromodomain-containing protein 7 (BRD7) was a direct tar-
get of miR-410. MiR-410-mediated downregulation of BRD7 led to increase Akt phosphorylation.
Inhibition of Akt phosphorylation can rescue the effect of miR-410 on NSCLC cell. The expression
of BRD7 was downregulated in NSCLC and was inversely expressed with miR-410 in NSCLC. Our data
provided new knowledge regarding the role of miR-410 in the lung cancer progression.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the most common type of cancers and the lead-
ing cause of cancer-related mortality worldwide. Non-small cell
lung cancers (NSCLC), including adenocarcinoma and squamous
cell carcinoma, account for approximately 85% of all lung cancer
cases [1–4]. Despite recent advances in clinical and experimental
oncology, the prognosis of NSCLC remains very poor with the
5-year survival rate a dismal 11% [5–8]. Therefore, a better
understanding of the detailed mechanisms of NSCLC is urgently
needed.
MicroRNAs (MiRNAs) are a class of single-stranded, small
non-coding RNAs that play important roles in all biological pro-
cesses through base pairing with the 30untranslated region
(30UTR) of target mRNAs [9–13]. Increasing evidences show thataberrant expression of miRNAs plays signiﬁcant roles in diverse
biological processes such as development, differentiation, growth,
and metabolism [13–16]. Meanwhile, deregulations of miRNAs
are observed in a wide range of cancers, including breast cancer,
gastric cancer, hepatocellular carcinoma, bladder cancer, osteosar-
coma and glioblastoma [17–23]. MiRNAs can function either as
tumor suppressor genes or oncogenes during tumor development
and progression [23–25].
Deregulated expression of miR-410 was found in various can-
cers, suggesting that miR-410 might play an important role in
tumor development and progression [26–29]. Previous result
showed that the expression of miR-410 was associated with dis-
ease free survival of the non-MYCN-ampliﬁed favorable neurob-
lastoma [27]. Furthermore, miR-410 was reported to negatively
regulate Rb/E2F pathway by directly targeting CDK1 in breast
cancer [30]. However, the role of miR-410 in NSCLC is still
unknown. In this study, we found that the expression of
miR-410 was increased in NSCLC tissues compared with the
matched normal lung tissues. Moreover, overexpression of
miR-410 promoted cell proliferation, migration and invasion in
NSCLC. Furthermore, bromodomain-containing protein 7 (BRD7)
was identiﬁed as a new direct target of miR-410. These results
suggested that high expression of miR-410 might be involved
in NSCLC carcinogenesis.
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2.1. Ethics statement
Written informed consent was obtained from all patients. All
experimental procedures were approved by the ethical board of
the institute of Chest hospital of Hebei province and complied with
the Declaration of Helsinki.
2.2. Tissue specimens and cell lines
NSCLC tissues and their corresponding adjacent non-tumor lung
tissues were obtained in our hospital from 2011 and 2013. No
patients had received blood transfusion, radiotherapy, or
chemotherapy before surgery. Tissue samples were immediately
snap-frozen in liquid nitrogen and stored in liquid nitrogen until
RNA extraction. Four Human NSCLC cell lines (A549, SPC-A1,
H1299, and H1650) and normal bronchial epithelial cell line
(16HBE) were obtained from the Chinese Academy of Sciences
(Shanghai, China). Cells were cultured in DMEM media
(Invitrogen, Carlsbad, CA, USA), which contained 10% FBS at 37 C
with 5% CO2.
2.3. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) analysis
Total RNA was extracted from the cultured cells or tissues using
TRIzol reagent (Invitrogen, USA). Relative expression of miR-410
was examined using SYBR green real-time PCR and normalized
with U6 snRNA. The primers of miR-410, U6 snRNA and miScript
SYBR Green PCR kit were collected from Qiagen for real-time
PCR. The real-time PCR reactions were performed on a 7500 Fast
System real-time PCR cycler (Applied Biosystems, USA) in accor-
dance with manufacturer’s instructions.
2.4. Western blot analysis
Western blotting was performed as previously described [15].
Membranes were probed with mouse polyclonal antibodies
(anti-AKT, anti-p-AKT, and anti-BRD7 antibody) (R&D Systems,
USA) at 4 C overnight or mouse monoclonal anti-GAPDH antibody
(Beyotime, China) for 1 h at 37 C. Then the membranes were incu-
bated with the horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG antibody (ZSGB-BIO, China). Protein bands were
visualized using an enhanced chemiluminescence kit (Amersham,
Little Chalfont, UK).
2.5. Oligonucleotides and transfection
miR-410 mimics, scramble and inhibitor and control were syn-
thesized by Dharmacon and transfected with Lipofectamine 2000
reagent (Invitrogen) following to the manufacturer’s instructions.
Transfection complexes were added directly to the cells to a ﬁnal
oligonucleotide concentration of 20 nmol/l. The full-length cDNA
of BRD7 (which included the ORF and 30UTR) was ampliﬁed and
cloned into pcDNA to generate the pcDNA-BRD7 constructs, which
was applied for the rescue experiment. A549 cells were ﬁrst trans-
fected with miR-410 mimic. Then, these cells were then trans-
fected with either pcDNA-BRD7 or pcDNA-empty.
2.6. Luciferase assay
Cells were seeded in 96-well plates and transfected with
pLuc-30-UTR, 10 ng Renilla and miRNA mimic or scramble using
the Lipofectamine 2000 reagent. After 48 h of transfection, ﬁreﬂyand Renilla luciferase activities were performed by the
Dual-Luciferase Reporter Assay System (Promega). The relative
ﬁreﬂy luciferase activities were measured by normalizing to
Renilla luciferase activities.
2.7. Cell proliferation, invasion and migration assays
Cell proliferation was detected using a CCK8 (Dojindo
Laboratories) according the manufacturer’s instructions. Cell inva-
sion was detected using a transwell chamber (Millipore, Billerica,
MA, USA) with Matrigel (BD, San Jose, CA, USA). Cells were cult
the top chamber of transwell coated with Matrigel. Cells were cul-
tured in mediumwith DMEM in the toper chamber and added with
FBS-DMEM in the lower chamber. After 24 h of incubation, invasive
cells on the lower chamber were stained with 0.5% crystal violet
and counted. Cell migration was detected using wound-healing
assay. An artiﬁcial wound was created by a 200-ll pipette tip.
Mitomyclin C was added to the culture wells. To visualize migrated
cells and wound healing, images were taken at 0 and 48 h.
2.8. Statistical analysis
Data was expressed as means ± S.D. (standard deviation).
One-way ANOVA was performed for serial analysis while two
treatment groups were compared by the unpaired Student’s t test.
Differences were considered statistically signiﬁcant when
P-value < 0.05.
3. Results
3.1. MiR-410 was upregulated in NSCLC and cell lines
The expression of miR-410 was upregulated in 26 cases (26/30,
87%) compared with adjacent tissues (Fig. 1A). Moreover, the
expression of miR-410 was upregulated in NSCLC tissues compared
to that in non-tumor normal tissues (Fig. 1B). The expression of
miR-410 in four NSCLC cell lines (A549, SPC-A1, H1299 and
H1650) was increased compared to that in 16HBE cells (Fig. 1C).
3.2. MiR-410 promoted the proliferation of NSCLC cell lines
The A549 cells were transfected with miR-410 mimics and inhi-
bitors, scrambled or control oligo, which exhibited high transfec-
tion efﬁciency (Fig. 2A). CCK-8 proliferation assay showed that
cell proliferation was increased in miR-410 mimics-transfected
A549 cells compared with the scrambled oligo-transfected cells
or untreated cells (Fig. 2B). In addition, knockdown of miR-410
repressed cell proliferation of the A549 cells (Fig. 2B).
3.3. MiR-410 promoted the migration and invasion of NSCLC cell
The percentage of migrated cells was higher in cells transfected
with miR-410 mimic and lower in cells transfected with miR-410
inhibitor (Fig. 3A). Furthermore, the percentage of invasive cell
was higher in cells transfected with miR-410 mimic and lower in
cells transfected with miR-410 inhibitor (Fig. 3B).
3.4. MiR-410 targeted BRD7 in NSCLC cell
To identify target genes of miR-410, Targetscan was used to ﬁnd
miR-410 the potential targets. As showed in Fig. 4A, there was
complementarily between miR-410 and the BRD7 30UTR.
Overexpression of miR-410 repressed the luciferase activity of
the reporter gene with the wild-type construct but not the mutant
BRD7 30UTR construct (Fig. 4B). Overexpression of miR-410
Fig. 1. miR-410 is highly expressed in NSCLC and cell lines. (A) qRT-PCR was used to detect miR-410 expression in 30 NSCLC and matched normal tissue samples. U6 snRNA
was used as internal control. (B) Relative miR-410 expression levels in NSCLC tissues and adjacent normal tissues were determined by qRT-PCR. U6 snRNA was used as
internal control. (C) The expression of miR-410 in four NSCLC cell lines, A549, SPC-A1, H1299 and H1650 was signiﬁcantly increased compared to that in the 16HBE cells. U6
snRNA was used as internal control. ***P < 0.001.
Fig. 2. miR-410 promotes the proliferation of NSCLC cell lines. (A) Expression levels of miR-410 were examined by real-time PCR after transfection of miR-410 mimics,
inhibitor or scramble or control in A549 cells. (B) Growth of A549 cells was shown after transfection with miR-410 mimics or scramble or no transfection. The growth index
was assessed at 0, 24, 48 and 72 h using CCK8 proliferation assay. **P < 0.01, and ***P < 0.001.
Fig. 3. miR-410 promotes the NSCLC cell migration and invasion. (A) Migration analysis of A549 cells after treatment with miR-410 mimics, inhibitors or scramble or control;
relative ratio of wound closure per ﬁeld is shown. (B) Invasion analysis of A549 cells after treatment with miR-410 mimics, inhibitors or scramble or control; the relative ratio
of invasive cells per ﬁeld is shown below, ***P < 0.001.
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Fig. 4. miR-410 targets BRD7 in NSCLC cell. (A) Schematic representation of BRD7 30 UTRs showing putative miR-410 target site. Predicted duplex formation between human
BRD7 30-UTR and miR-410, BRD7 30-UTR is highly conserved in different species. (B) The analysis of the relative luciferase activities of BRD7-WT, BRD7-MUT in A549 cells. The
error bars are derived from triplicate experiments. (C) qRT-PCR analysis of BRD7 mRNA expression in A549 cells after treatment with miR-410 mimics or scramble or no
transfection. The expression of BRD7 was normalized to GAPDH. (D) Western blot analysis of BRD7 expression in A549 cells transfected with miR-410 mimics or scramble or
no transfection. GAPDH was also detected as a loading control. ***P < 0.001.
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(Fig. 4C and D).
3.5. MiR-410 induced cell proliferation in the AKT-dependent pathway
Overexpression of miR-410 increased the expression of p-AKT
in A549 cells and knockdown of miR-410 decreased the expression
of p-AKT in the A549 cells (Fig. 5A). Moreover, downregulation of
BRD7 led high AKT phosphorylation (Fig. 5B). Furthermore, knock-
down of BRD7 by siRNA partially abrogated the function of BRD7
induced by miR-410 inhibitor (Fig 5C). Importantly, knockdown
of Akt expression repressed miR-410 mimic induced A549 cell pro-
liferation (Fig. 5D). Inhibition of BRD7 enhanced cell proliferation
in A549 cells (Fig. 5E). In addition, knockdown of BRD7 could
reverse the proliferation inhibition imposed by miR-410 inhibitor
(Fig. 5E).
3.6. Re-expression of BRD7 reversed the miR-410-induced cell
proliferation
The expression of BRD7 was increased using pcDNA-BRD7
(Fig. 6A). We rescued the expression of BRD7 in cells overexpress-
ing miR-410. Overexpression of BRD7 decreased the cells prolifer-
ation induced by miR-410 (Fig. 6B).
3.7. The expression of BRD7 was downregulated in NSCLC and was
inversely expressed with miR-410 in NSCLC
The expression of BRD7 was downregulated in 26 NSCLC cases
(26/30, 87%) compared with adjacent tissues (Fig. 7A). Moreover,
the expression of BRD7 was decreased in NSCLC tissues compared
to that in non-tumor normal tissues (Fig. 7B). Moreover, the
expression of BRD7 was inversely correlated with the expression
of miR-410 in NSCLC tissues (Fig. 7C).
4. Discussion
Aberrantly expressed miRNAs play a crucial role in carcinogen-
esis [31–34]. In recent years increasing studies have indicated thatderegulation of miRNAs expression is implicated in many aspects
of cancers, functioning as either tumor suppressors or oncogenes
[33,35–38]. In this study, the expression of miR-410 was higher
in NSCLC tissues compared with the matched normal lung tissues.
Moreover, overexpression of miR-410 increased cell proliferation,
migration and invasion in NSCLC cells. Furthermore, we have iden-
tiﬁed BRD7 as a novel direct target of miR-410. Additionally, over-
expression of miR-410 led to increased Akt signaling by directly
targeting BRD7. Re-expression of BRD7 reversed the
miR-410-induced cell proliferation. The expression of BRD7 was
downregulated in 26 NSCLC cases (26/30, 87%) compared with
adjacent tissues. The expression level of BRD7 was inversely corre-
lated with the expression level of miR-410 in NSCLC tissues. These
ﬁndings suggested that high expression of miR-410 might be
involved in NSCLC carcinogenesis and might be potential novel
therapeutic targets in treatment of NSCLC.
Aberrant expression of miR-410 is frequent in many cancers,
suggesting that miR-410 might play a crucial role in tumor devel-
opment and progression [26–29]. Previous result showed that the
expression of miR-410 was associated with disease free survival of
the non-MYCN-ampliﬁed favorable neuroblastoma [27].
Furthermore, miR-410 was reported to negatively regulate
Rb/E2F pathway by directly targeting CDK1 in breast cancer [30].
Recently, Wang et al. showed that miR-410 was overexpressed in
liver and colorectal tumors and enhanced tumor cell growth by
silencing FHL1 [29]. Consequently, it was supposed that deregula-
tion of miR-410 might occur in a tissue-speciﬁc manner in differ-
ent types of cancer. However, the roles of miR-410 in lung
cancer, particularly the NSCLC are unknown. In our study, the
expression of miR-410 was higher in NSCLC tissues compared with
the matched normal lung tissues. Furthermore, miR-410 promoted
NSCLC cell proliferation, migration and invasion. These results sug-
gest that miR-410 might act as a new oncogene in the progression
and metastasis of NCSLC.
Using the bioinformatics tool (Targetscan), we demonstrated
that miR-410 bound to the 30-UTR of BRD7. BRD7 is downregulated
in various malignancies, which encourage us to believe that BRD7
may be a miR-410 direct target in NSCLC [39–41]. In addition,
miR-410 inhibited BRD7 mRNA and protein expression. We also
Fig. 5. miR-410 induces cell proliferation in the AKT-dependent pathway (A) miR-410 mimic promote p-AKT expression in A549 cells; miR-410 inhibitor signiﬁcantly
repressed the expression of p-AKT in the A549 cells. GAPDH was also detected as a loading control. (B) Inhibition of BRD7 induces AKT phosphorylation. GAPDH was also
detected as a loading control. (C) Knockdown of BRD7 by siRNA partially abrogated the down-expression of BRD7 induced by miR-410 inhibitor. (D) Inhibition of AKT activity
by an AKT inhibitor (Wortmannin) repressed miR-410 mimic induced A549 cell proliferation. (E) Knockdown of BRD7 could signiﬁcantly reverse the proliferation inhibition
imposed by miR-410 inhibitor. *P < 0.05, **P < 0.01, and ***P < 0.001.
Fig. 6. Re-expression of BRD7 reversed the miR-410 induced cell proliferation. (A) The protein level of BRD7 was measured using Western blot. (B) CCK8 assay showed that
overexpression of BRD7 decreased the miR-410 overexpressing A549 cells proliferation. *P < 0.05, and ***P < 0.001.
Fig. 7. The expression of BRD7 was downregulated in NSCLC and was inversely expressed with miR-410 in NSCLC. (A) qRT-PCR was used to detect BRD7 expression in 30
NSCLC and matched normal tissue samples. GAPDH was used as internal control. (B) The expression of BRD7 was decreased in NSCLC tissues compared to that in non-tumor
normal tissues. (C) The expression of BRD7 was inverse correlation with the expression of miR-410 in NSCLC tissues (two-tailed Pearson’s correlation analysis, r2 = 0.554;
P < 0.001). ***P < 0.001.
2222 D. Li et al. / FEBS Letters 589 (2015) 2218–2223observed that the BRD7 could mediate the function of miR-410 in
the proliferation of NSCLC cells. BRD7 is a subunit of SWI/SNF com-
plex and is suggested as a novel tumor suppressor in several can-
cers such as epithelial ovarian cancer, Nasopharyngeal Cancer,
Colorectal Cancer and Endometrial Cancer [39,40,42–44].Moreover, BRD7 plays critical roles in diverse biological processes
such as cell development, differentiation, growth, and metabolism
[45–47]. Furthermore, Chiu et al. indicated that BRD7 could serve
as a tumor suppressor not only by promoting p53 function, but also
by reducing the survival signaling mediated by PI3K/Akt activation
D. Li et al. / FEBS Letters 589 (2015) 2218–2223 2223[48]. In this study, downexpression of BRD7 increased AKT phos-
phorylation and cell proliferation in NSCLC cells. However, the
underlying mechanisms were still unclear. In NSCLC cells,
miR-410 overexpression induced Akt phosphorylation while
knockdown of miR-410 attenuated such induction. Importantly,
inhibition of Akt activation partially blocked miR-410-induced cell
proliferation. Moreover, we demonstrated that the expression of
BRD7 was downregulated in 26 NSCLC cases (26/30, 87%) com-
pared with adjacent tissues. Furthermore, the expression of BRD7
was inverse correlation with the expression of miR-410 in NSCLC
tissues. We ﬁrst demonstrated that miR-410 was a new modulator
regulator of BRD7 in NSCLC cells, which provided one possible
mechanism for the role of miR-410 in NSCLC proliferation, invasion
and migration.
In conclusion, we demonstrated for the ﬁrst time that miR-410
acted as an oncogene in NSCLC through inhibiting the expression of
BRD7. These data suggest a novel therapeutic application of
miR-410 in NSCLC.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.06.
031.
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